Traws Pharma Delays Flu Drug Trial Amid Regulatory Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2025
0mins
Source: Newsfilter
Traws Pharma Inc. experienced a significant drop of 28.12% in regular trading as it crossed below its 5-day SMA.
The company announced a delay in its Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) due to a negative review from the UK's MHRA, which has raised concerns about its market timing and competitiveness in influenza treatment. Despite demonstrating strong efficacy in animal models, this regulatory feedback may hinder Traws Pharma's emergency response capabilities during influenza outbreaks. The CEO reaffirmed the company's commitment to advancing long-acting influenza antivirals, emphasizing the importance of these treatments for vulnerable populations.
The delay has led to a shift in market sentiment, with analysts maintaining a 'Buy' rating and a price target suggesting over 300% upside potential. Traws Pharma's solid financial position, with a cash runway extending to Q1 2027, positions it well to navigate these regulatory challenges and continue its R&D efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRAW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRAW
Wall Street analysts forecast TRAW stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.861
Low
8.00
Averages
8.00
High
8.00
Current: 0.861
Low
8.00
Averages
8.00
High
8.00
About TRAW
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Traws Pharma Delays Key Study for Flu Drug
- Study Delay Impact: Traws Pharma announced a delay in the human study for its lead flu drug tivoxavir marboxil due to feedback from the UK’s MHRA, resulting in a roughly 28% drop in after-hours trading, indicating market concerns over its development progress.
- Regulatory Response: The company is actively addressing the regulators' concerns, and despite the challenges, Traws believes the drug has potential for treating and preventing serious bird flu infections, emphasizing its strong efficacy in animal models.
- Cash Flow Assurance: Traws Pharma stated that its cash runway extends into the first quarter of 2027, and although the flu drug development has faced setbacks, the program remains a high priority, reflecting the company's confidence in future prospects.
- Market Sentiment Shift: On Stocktwits, retail sentiment around TRAW shifted from 'bearish' to 'neutral', with message volume improving, while analysts rate the stock as a 'Buy' with a 12-month price target of $5.5, implying over 300% upside potential.
See More
Traws Pharma Defers Influenza Drug Trial Due to Regulatory Review
- Trial Delay: Traws Pharma announced that the planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been deferred due to a negative review from the UK's MHRA, potentially impacting the company's market timing and competitiveness in influenza treatment.
- Strong Animal Efficacy: Despite demonstrating potent efficacy in three animal models of highly pathogenic avian influenza, the regulatory feedback delay may hinder the company's emergency response capabilities during influenza outbreaks, particularly among high-risk populations.
- Commitment to R&D: The CEO of Traws Pharma emphasized that, despite regulatory challenges, the company remains committed to advancing long-acting influenza antivirals, highlighting the importance of influenza treatment for vulnerable groups such as the elderly and immunocompromised individuals.
- Solid Financial Position: With a cash runway extending to Q1 2027, the company is well-positioned to address regulatory concerns and advance alternative candidates, ensuring ongoing investment and innovation in the influenza prevention and treatment sector.
See More
Traws Pharma Q1 Earnings Beat Expectations
- Earnings Performance: Traws Pharma reported a Q1 GAAP EPS of -$0.53, beating expectations by $0.03, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Flow Status: As of March 31, 2026, the company had approximately $3.1 million in cash and cash equivalents, down from $3.8 million as of December 31, 2025, reflecting pressure on the company's financial management.
- Funding Plans: The company believes its current cash balance, along with proceeds from financing, is sufficient to support planned expenses, including the completion of the Challenge Study, into Q1 2027, demonstrating confidence in future operations.
- Financing Dynamics: Traws Pharma is pursuing a $60 million PIPE financing to support its upcoming flu challenge study, a move that not only secures funding but also potentially enhances its competitive position in the flu vaccine market.
See More
Healthcare Stocks Decline Late Friday Afternoon
- Healthcare Sector Decline: Late Friday afternoon, the NYSE Healthcare Index experienced a decline, indicating a weakening market confidence in the healthcare sector, which may affect investors' short-term decisions.
- Market Sentiment Deterioration: The widespread drop in healthcare stocks could lead investors to reassess their portfolios in the healthcare sector, resulting in increased capital outflows and heightened market volatility.
- Significant Industry Impact: The decline in healthcare stocks may trigger a ripple effect on related companies' stock prices, impacting their financing capabilities and future growth expectations, especially in the current uncertain economic environment.
- Investor Focus Shift: As healthcare stocks weaken, investors may redirect their attention to other sectors in search of more attractive investment opportunities, potentially affecting capital inflows into the healthcare industry.
See More
Traws Pharma Advances Hantavirus Treatment Development
- Stock Surge: Traws Pharma (TRAW) shares jumped 30% in early trading after announcing plans to advance potential clinical candidates for hantavirus treatment, reflecting strong market confidence in its new direction, particularly against larger vaccine makers like Moderna and Inovio.
- Hantavirus Context: Hantavirus is a severe rodent-borne disease with a fatality rate of 30% to 50%; although the World Health Organization states that the outbreak is unlikely to become a pandemic like COVID-19, vigilance is necessary due to the potential for increased cases.
- Leveraging R&D Experience: Traws Pharma indicated that its experience in developing antiviral drugs for influenza, H5N1 bird flu, and COVID-19 could expedite the development of new treatments for hantavirus, especially given the lack of approved therapies for the disease.
- Market Sentiment Shift: Retail sentiment for TRAW on Stocktwits shifted from 'bearish' to 'extremely bullish', with message volumes surging 820% in the past 24 hours, indicating optimistic investor expectations for the company's future, with one user suggesting a potential 20x increase in stock value if a major outbreak occurs.
See More
Traws Pharma Advances Hantavirus Treatment Candidates Amid Rising Threats
- Hantavirus Threat: Traws Pharma is developing clinical candidates targeting hantavirus, which has a fatality rate of 30-50% and has recently caused serious illnesses on cruise ships, highlighting the urgent need for effective treatments to address public health crises.
- Antiviral Drug Development: The company plans to rapidly advance clinical candidates for hantavirus treatment using its extensive antiviral drug assets, with candidates already tested for their ability to inhibit negative-strand virus replication, demonstrating promising potential.
- Strategic Collaboration and Resource Integration: Traws Pharma will leverage its established drug development network and virus testing assets to swiftly identify optimal treatment candidates while accessing proprietary chemical libraries to refine treatment options, enhancing its competitive edge in the market.
- National Security Considerations: With the frequent resurgence of hantavirus in the Southwest United States and other regions, Traws Pharma emphasizes the critical importance of developing life-saving treatments to respond to emergent outbreaks and ensure national security.
See More
Traws Pharma Delays Key Study for Flu Drug
- Study Delay Impact: Traws Pharma announced a delay in the human study for its lead flu drug tivoxavir marboxil due to feedback from the UK’s MHRA, resulting in a roughly 28% drop in after-hours trading, indicating market concerns over its development progress.
- Regulatory Response: The company is actively addressing the regulators' concerns, and despite the challenges, Traws believes the drug has potential for treating and preventing serious bird flu infections, emphasizing its strong efficacy in animal models.
- Cash Flow Assurance: Traws Pharma stated that its cash runway extends into the first quarter of 2027, and although the flu drug development has faced setbacks, the program remains a high priority, reflecting the company's confidence in future prospects.
- Market Sentiment Shift: On Stocktwits, retail sentiment around TRAW shifted from 'bearish' to 'neutral', with message volume improving, while analysts rate the stock as a 'Buy' with a 12-month price target of $5.5, implying over 300% upside potential.
See More
Traws Pharma Defers Influenza Drug Trial Due to Regulatory Review
- Trial Delay: Traws Pharma announced that the planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been deferred due to a negative review from the UK's MHRA, potentially impacting the company's market timing and competitiveness in influenza treatment.
- Strong Animal Efficacy: Despite demonstrating potent efficacy in three animal models of highly pathogenic avian influenza, the regulatory feedback delay may hinder the company's emergency response capabilities during influenza outbreaks, particularly among high-risk populations.
- Commitment to R&D: The CEO of Traws Pharma emphasized that, despite regulatory challenges, the company remains committed to advancing long-acting influenza antivirals, highlighting the importance of influenza treatment for vulnerable groups such as the elderly and immunocompromised individuals.
- Solid Financial Position: With a cash runway extending to Q1 2027, the company is well-positioned to address regulatory concerns and advance alternative candidates, ensuring ongoing investment and innovation in the influenza prevention and treatment sector.
See More
Traws Pharma Q1 Earnings Beat Expectations
- Earnings Performance: Traws Pharma reported a Q1 GAAP EPS of -$0.53, beating expectations by $0.03, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Flow Status: As of March 31, 2026, the company had approximately $3.1 million in cash and cash equivalents, down from $3.8 million as of December 31, 2025, reflecting pressure on the company's financial management.
- Funding Plans: The company believes its current cash balance, along with proceeds from financing, is sufficient to support planned expenses, including the completion of the Challenge Study, into Q1 2027, demonstrating confidence in future operations.
- Financing Dynamics: Traws Pharma is pursuing a $60 million PIPE financing to support its upcoming flu challenge study, a move that not only secures funding but also potentially enhances its competitive position in the flu vaccine market.
See More
Healthcare Stocks Decline Late Friday Afternoon
- Healthcare Sector Decline: Late Friday afternoon, the NYSE Healthcare Index experienced a decline, indicating a weakening market confidence in the healthcare sector, which may affect investors' short-term decisions.
- Market Sentiment Deterioration: The widespread drop in healthcare stocks could lead investors to reassess their portfolios in the healthcare sector, resulting in increased capital outflows and heightened market volatility.
- Significant Industry Impact: The decline in healthcare stocks may trigger a ripple effect on related companies' stock prices, impacting their financing capabilities and future growth expectations, especially in the current uncertain economic environment.
- Investor Focus Shift: As healthcare stocks weaken, investors may redirect their attention to other sectors in search of more attractive investment opportunities, potentially affecting capital inflows into the healthcare industry.
See More
Traws Pharma Advances Hantavirus Treatment Development
- Stock Surge: Traws Pharma (TRAW) shares jumped 30% in early trading after announcing plans to advance potential clinical candidates for hantavirus treatment, reflecting strong market confidence in its new direction, particularly against larger vaccine makers like Moderna and Inovio.
- Hantavirus Context: Hantavirus is a severe rodent-borne disease with a fatality rate of 30% to 50%; although the World Health Organization states that the outbreak is unlikely to become a pandemic like COVID-19, vigilance is necessary due to the potential for increased cases.
- Leveraging R&D Experience: Traws Pharma indicated that its experience in developing antiviral drugs for influenza, H5N1 bird flu, and COVID-19 could expedite the development of new treatments for hantavirus, especially given the lack of approved therapies for the disease.
- Market Sentiment Shift: Retail sentiment for TRAW on Stocktwits shifted from 'bearish' to 'extremely bullish', with message volumes surging 820% in the past 24 hours, indicating optimistic investor expectations for the company's future, with one user suggesting a potential 20x increase in stock value if a major outbreak occurs.
See More
Traws Pharma Advances Hantavirus Treatment Candidates Amid Rising Threats
- Hantavirus Threat: Traws Pharma is developing clinical candidates targeting hantavirus, which has a fatality rate of 30-50% and has recently caused serious illnesses on cruise ships, highlighting the urgent need for effective treatments to address public health crises.
- Antiviral Drug Development: The company plans to rapidly advance clinical candidates for hantavirus treatment using its extensive antiviral drug assets, with candidates already tested for their ability to inhibit negative-strand virus replication, demonstrating promising potential.
- Strategic Collaboration and Resource Integration: Traws Pharma will leverage its established drug development network and virus testing assets to swiftly identify optimal treatment candidates while accessing proprietary chemical libraries to refine treatment options, enhancing its competitive edge in the market.
- National Security Considerations: With the frequent resurgence of hantavirus in the Southwest United States and other regions, Traws Pharma emphasizes the critical importance of developing life-saving treatments to respond to emergent outbreaks and ensure national security.
See More
